XML 258 R201.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Other operating expenses - Other Income and Expense (Details) - EUR (€) € in Millions | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |  |  |
Other operating expenses |  | € (4,382) | € (3,443) | [1] | € (2,523) | [1]
Other operating income |  | 1,089 | 979 | [1] | 1,814 | [1]
Other operating income/(expenses), net related to Regeneron |  | (3,789) | (2,979) |  | (1,231) |
Antibodies Collaboration agreement | Regeneron Pharmaceuticals, INC |  |  |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |  |  |
Commitments received for development costs |  | 1,600 | 2,100 |  |  |
Regeneron |  |  |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |  |  |
Other operating expenses |  | (3,955) | (3,206) |  | (2,378) |
Other operating income (expense) | Regeneron |  |  |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |  |  |
Other operating income |  | 166 | 227 |  | 1,147 |
Monoclonal Antibody Alliance |  |  |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |  |  |
Other operating expenses |  | (3,947) | (3,196) |  | (2,367) |
Monoclonal Antibody Alliance | Share of profit or loss from commercialization of monoclonal antibodies |  |  |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |  |  |
Other operating expenses |  | (4,143) | (3,321) |  | (2,325) |
Monoclonal Antibody Alliance | Share of profit or loss from commercialization of Zaltrap |  |  |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |  |  |
Other operating income | [2] | 833 | 668 |  | 434 |
Monoclonal Antibody Alliance | Commercialization related expenses |  |  |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |  |  |
Other operating expenses |  | (637) | (543) |  | (476) |
Immuno-Oncology Alliance |  |  |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |  |  |
Other operating income |  | 0 | 0 |  | 16 |
Others |  |  |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |  |  |
Other operating income and expenses |  | € 158 | € 217 |  | € 1,120 |
[1] | Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] | (a)As of December 31, 2024, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to €1.6 billion, compared with €2.1 billion as of December 31, 2023 (see Note D.21.).

X
- Definition The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_MiscellaneousOtherOperatingExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of miscellaneous other operating income. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_MiscellaneousOtherOperatingIncome
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of operating income (expense) that the entity does not separately disclose in the same statement or note. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 85 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_OtherOperatingIncomeExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commitments Received For Development Costs + References No definition available. + Details
Name: | sny_CommitmentsReceivedForDevelopmentCosts
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Disclosure of other operating income (expenses). + References No definition available. + Details
Name: | sny_DisclosureOfOtherOperatingIncomeExpensesLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other operating income and expenses. + References No definition available. + Details
Name: | sny_MiscellaneousOtherOperatingIncomeExpenses
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_IncomeStatementLocation1Axis=sny_OtherOperatingIncomeExpense1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_IncomeStatementLocation1Axis=sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_IncomeStatementLocation1Axis=sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_IncomeStatementLocation1Axis=sny_CommercializationRelatedExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sny_ImmunooncologyAllianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sny_OthersCounterpartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |